Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Belgium /
      2. How we work /
      3. Transparency/
      4. Transfer of value

      Transfer of value

      Why a Disclosure of Transfer of Value Code?

      Johnson & Johnson has a track record of delivering innovative and sometimes lifesaving medicines to society based on our research and our co-operation with doctors, medical scientists, hospitals and other healthcare professionals (HCPs) as well as with healthcare organisations (HCOs). This co-operation has delivered great outcomes for patients.

      In June 2013, the European Federation of Pharmaceutical Industries and Associations (EFPIA) formally adopted the ‘Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ in an effort to further self-regulate the way pharmaceutical companies collaborate with HCPs or their organisations when value transfer (such as fees for consultancy services or educational grants) is involved.
      betransparant.be
      Pensive woman wrapped in blanket looking at sunset ocean
      Understanding the working relationship between the pharmaceutical industry and healthcare
      In June 2016, Johnson & Johnson along with other pharmaceutical companies who are members of EFPIA, published transfers of value made during 2015, such as financial support provided to HCPs to attend educational meetings, fees for services provided to Johnson & Johnson by HCPs or educational grants to HCOs. Moving forwards, transfers of value will be published in June on an annual basis for transactions made during the previous calendar year.
      We believe open communication about these interactions is good for everyone because it helps demonstrate that patients benefit from these interactions, in the form of more informed clinical decision-making and the appropriate use of medicines.

      Johnson & Johnson wholeheartedly supports the disclosure of transfers of value. The EFPIA Disclosure Code and corresponding country-level industry association codes represent an important milestone on our journey to achieving greater transparency in the way that industry and the medical community work together. These relationships are essential for furthering our understanding of disease, continuously progressing the advancement of medicines and ultimately enhancing outcomes for patients.